Branaplam
CHEMICAL COMPOUND
NVS-SM1; LMI070; LMI-070; C22H27N5O2
Branaplam (development codes LMI070 and NVS-SM1) is a pyridazine derivative that is being studied as an experimental drug. It was originally developed by Novartis to treat spinal muscular atrophy (SMA); since 2020 it is being developed to treat Huntington's disease (HD).